NEW YORK (AP) — French drugmaker Sanofi said Tuesday that it is seeking marketing approval for its multiple sclerosis drug Lemtrada in the U.S. and European Union.
Sanofi's Genzyme unit is developing the drug through a partnership with Bayer HealthCare. In December, Sanofi filed for approval of another multiple sclerosis drug, Aubagio.
Sanofi's U.S. shares rose 21 cents to $34.40 in morning trading in New York. They have traded in a 52-week range of $30.98 to $40.58.